¿´Æ¬ÊÓƵ

Object moved to here.

¿´Æ¬ÊÓƵ :: Pilot & Feasibility Program Application

¿´Æ¬ÊÓƵ


Characterization of a new model of diabetic retinopathy
Summary Data Summary
Applicant Alpers, Charles
E-Mail Address calp@u.washington.edu
Project Title Characterization of a new model of diabetic retinopathy
CBU ID 12GHSU187
External SubContract ID 25034-22
Diabetic Complication Nephropathy
Funding Program Group Pilot & Feasibility [PF2012]
Abstract Diabetic retinopathy (DR) is a major, common, and specific manifestation of
diabetes, that has been estimated to be present in 86% of T1D patients.
Approximately half of affected patients (42% off all T1D patients), will have
vision-threatening retinopathy. The lack of a good model of this microvascular
complication has hampered development and testing of effective therapeutics for
DR. We present exciting preliminary data that the BTBR ob/ob murine model of
Type II diabetes may develop a proliferative microvascular retinopathy,
concurrently with other retinal and microvascular complications of diabetes. The
development of diabetes and diabetic complications in this model is the
consequence of a genetic mutation resulting in leptin deficiency. Leptin
replacement in these mice has been demonstrated by us to effect the reversal of
diabetes and, in the case of the kidney, reverse the functional and structural
manifestations of advanced diabetic nephropathy. Whether such a dramatic
reversal of DR can also be achieved is unknown. We have been exploring the
possibility of adapting a new imaging technology (OMAG) for studies of diabetic
complications of microvascular origin that can allow investigators to follow the
development of DR lesions sequentially over time in the living mouse. Building
on these advances in diabetic model development, we propose the following
specific aims:
Specific Aim #1: To characterize a new mouse model of diabetic retinopathy (DR)
and to test the potential for reversal of DR by maneuvers previously shown to
reverse diabetic nephropathy in the BTBR ob/ob mouse model of Type 2
Diabetes.Specific Aim #2: to establish a new and non-invasive imaging approach
for monitoring and quantitating the development of DR and its potential reversal
in the live animal setting, that is directly relevant to the management of
humans with DR or at risk to develop DR. Establishing a robust model of DR will
enable us and others to better test therapies of potential benefit to humans
with DR or at risk for DR in a preclinical setting, and will enable focused
studies of the pathogenesis of DR and identify pathophysiologic pathways that
result in progression or regression of this lesion.
Application PDF Application Research Plan
Status Contract Executed
Key Personnel
Salary Total Costs 51948
Supply Total Costs 14000
Equipment Total Costs 0
Travel/Other Total Costs 21500
Direct Costs 87448
Indirect Costs Proposed 8745
Total Costs Proposed 96193
Total Costs Approved 96193
Start Date 10/1/2012
End Date 9/30/2013
IFO Name Chronister, Lynne
IFO E-Mail Address lchronis@u.washington.edu
IACUC/IRB No. 2281-06
IACUC/IRB Institution University of Washington
Entity ID No.
Report Request Date 10/30/2013
T1D NO
TypeCount
Invoices 14
Progress Reports 1
Experiments 1
Data Submission


Invoices
UrlCBU IDExternal IDInstitutionDateDirectIndirectInvoiceBalancePDF
  View  12GHSU18725034-22University of Washington9/10/2013$9,629.80$962.98$10,592.78$2.78View PDF
  View  12GHSU18725034-22University of Washington8/9/2013$11,367.59$1,136.76$12,504.35$2.78View PDF
  View  12GHSU18725034-22University of Washington7/10/2013$7,020.96$702.10$7,723.06$2.78View PDF
  View  12GHSU18725034-22University of Washington6/10/2013$4,485.37$448.54$4,933.91$2.78View PDF
  View  12GHSU18725034-22University of Washington5/10/2013$5,457.34$545.74$6,003.08$2.78View PDF
  View  12GHSU18725034-22University of Washington4/10/2014$1,038.74-$1,038.74$2.78View PDF
  View  12GHSU18725034-22University of Washington4/10/2013$3,011.35$301.14$3,312.49$2.78View PDF
  View  12GHSU18725034-22University of Washington3/11/2014$2,514.51$251.46$2,765.97$2.78View PDF
  View  12GHSU18725034-22University of Washington3/11/2013$17,788.60$1,778.87$19,567.47$2.78View PDF
  View  12GHSU18725034-22University of Washington2/11/2014$1,185.50$118.56$1,304.06$2.78View PDF
  View  12GHSU18725034-22University of Washington12/10/2013$4,630.33$463.04$5,093.37$2.78View PDF
  View  12GHSU18725034-22University of Washington11/12/2013$5,610.22$561.03$6,171.25$2.78View PDF
  View  12GHSU18725034-22University of Washington10/10/2013$7,634.24$763.42$8,397.66$2.78View PDF
  View  12GHSU18725034-22University of Washington1/9/2014$6,165.48$616.55$6,782.03$2.78View PDF


Reports


Experiments
Click here to cancel and return to funding program application

*Author:
*SubContract:
*Select File:

Click browse and select the file to upload.
(Please upload ONLY TXT, Image Files (not histolgy), PDF, XLS, XLSX, DOC, or DOCX files.)